Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7794720 | 0.85 | AHR (0.51) | HPGDMAPTALDH1A1KDM4EGAA | |
| SCHEMBL23962919 | 0.74 | HPGD (0.50) | HPGDMAPTALDH1A1KDM4EGAA | |
| SCHEMBL1306411 | 0.70 | GLS (0.53) | HPGDKMT2AMEN1 | |
| SCHEMBL21335854 | 0.67 | AHR (0.52) | HPGDMAPTALDH1A1KDM4EGAA | |
| SCHEMBL21761651 | 0.67 | SMN1; SMN2 (0.37) | HPGDALDH1A1GAAKMT2AMAPK1 | |
| SCHEMBL7009198 | 0.66 | MEN1 (0.52) | HPGDMAPTALDH1A1KDM4EGAA | |
| SCHEMBL21761627 | 0.66 | CA1 (0.39) | HPGDALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL12284941 | 0.66 | SMN1; SMN2 (0.59) | HPGDMAPTALDH1A1GAAKMT2A | |
| SCHEMBL14876516 | 0.65 | CA12 (0.53) | HPGDMAPTALDH1A1KDM4EGAA | |
| SCHEMBL24182074 | 0.65 | AHR (0.50) | HPGDMAPTALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337964-B2 | Isoindoline derivative, pharmaceutical composition and use thereof | PDE4A, PDE4B, PDE4C | HPGD 80/4885MAPT 1210/4885ALDH1A1 489/4885 |
| US-20200061033-A1 | NOVEL ISOINDOLINE DERIVATIVE, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | HPGD 122/4885MAPT 1566/4885ALDH1A1 773/4885 |
| US-20220152002-A1 | ISOINDOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDE4A, PDE4B, PDE4C | HPGD 81/4885MAPT 1273/4885ALDH1A1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.